This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Amarin (AMRN) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Amarin (AMRN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stocks to Buy for June 10th
by Zacks Equity Research
AMRN, FIX and PATH made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 10, 2025.
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM
by Zacks Equity Research
ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.
New Strong Buy Stocks for June 10th
by Zacks Equity Research
FIX, GHLD, AMRN, VCISY and NWFL have been added to the Zacks Rank #1 (Strong Buy) List on June 10, 2025.
KURA Stock Rises More Than 15% This Past Week: Here's Why
by Zacks Equity Research
Kura Oncology shares rise this week after the FDA accepts its NDA for ziftomenib, a potential first-in-class treatment for NPM1-mutant AML.
Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio?
by Zacks Equity Research
ZTS jumps 13% in a month as strong new product sales, strategic deals, and rising earnings estimates boost investor confidence.
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success
by Zacks Equity Research
LYRA skyrockets 356% after its lead nasal implant, LYR-210, meets key goals in a pivotal phase III chronic rhinosinusitis study.
JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer
by Zacks Equity Research
Johnson & Johnson's niraparib combo significantly delays prostate cancer progression in HRR-altered patients with strong phase III data.
SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease
by Zacks Equity Research
Sanofi's rilzabrutinib earns its fourth orphan drug status from the FDA, this time targeting sickle cell disease.
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug
by Zacks Equity Research
KYMR jumps after KT-621 phase I data beats expectations, matching or topping Dupixent on key biomarkers in Th2 diseases.
Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase III
by Zacks Equity Research
AMGN's Imdelltra slashes lung cancer death risk by 40% in Phase III, extending survival by over five months compared to chemotherapy.
Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines
by Zacks Equity Research
SNY's $9.5 billion deal to acquire BPMC boosts its immunology pipeline and adds fast-growing Ayvakit to its portfolio.
IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus
by Zacks Equity Research
Immunovant stock rises on encouraging fourth-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.
ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study
by Zacks Equity Research
ORIC Pharmaceuticals stock rises 20% pre-market on early data showing strong PSA responses and tolerability for prostate cancer drug ORIC-944 in phase Ib study.
BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications
by Zacks Equity Research
Bristol Myers' Opdivo SC wins EU approval as the first PD-1 inhibitor for subcutaneous use across multiple solid tumor indications.
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer
by Zacks Equity Research
Candel stock rises as FDA grants RMAT tag to CAN-2409 after phase III success in prostate cancer. BLA submission is planned at the end of 2026.
Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how GSK (GSK) and Amarin (AMRN) have performed compared to their sector so far this year.
RCKT Stock Tanks on Patient Death in Danon Disease Study
by Zacks Equity Research
Rocket Pharmaceuticals plunges after a patient death in its Danon disease study, prompting a voluntary dosing pause. The FDA puts a clinical hold on the study.
TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate
by Zacks Equity Research
TEVA starts IND-enabling studies for BD9, a dual-targeting multibody for asthma and eczema. Shares rise on the news.
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval
by Zacks Equity Research
Verastem Oncology jumps 22% on FDA nod for Avmapki Fakzynja, the first approved KRAS-mutant LGSOC therapy, with strong early data in a pancreatic cancer study.
AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer
by Zacks Equity Research
AstraZeneca wins CHMP nod for Imfinzi combo in muscle-invasive bladder cancer, based on data from the phase III NIAGARA study.
GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma
by Zacks Equity Research
GSK wins CHMP nod for Blenrep combos in relapsed or refractory multiple myeloma. A decision in the EU is expected in the third quarter of 2025.
SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease
by Zacks Equity Research
SWTX wins CHMP backing for mirdametinib in NF1-PN. EU nod is expected in the third quarter of 2025.
Bayer Gets CHMP Nod for Eylea 8 mg in the EU for 2 Major Eye Diseases
by Zacks Equity Research
BAYRY's Eylea 8 mg gets CHMP nod in EU, promising 6-month dosing for nAMD and DME with strong 3-year efficacy and safety data.
EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort
by Zacks Equity Research
Exelixis' zanzalintinib/Opdivo combo shows superior efficacy for treating kidney cancer in an expansion cohort of the phase Ib/II STELLAR-002 study.